26
Participants
Start Date
November 9, 2021
Primary Completion Date
March 22, 2023
Study Completion Date
April 12, 2023
Imprime PGG
Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
Pembrolizumab
Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
The University of Arizona Cancer Center - North Campus, Tucson
Columba University Medical Center, New York
Stony Brook University, Stony Brook
Thomas Jefferson University- Sidney Kimmel Cancer Center, Philadelphia
University of Miami and Clinics -Sylvester Comprehensive Cancer Center, Miami
Mt. Sinai (Miami), Miami Beach
Moffitt Cancer Center, Tampa
Baptist Clinical Research Institute, Memphis
HealthPartners Cancer Research Center, Saint Louis Park
St. Vincent - Frontier Cancer Center, Billings
St. Luke's Cancer Institute, Kansas City
Louisiana State University Health Sciences Center - New Orleans, New Orleans
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado at Denver, Denver
The University of Arizona Cancer Center, Tucson
University of New Mexico Comprehensive Cancer Center, Albuquerque
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
HiberCell, Inc.
INDUSTRY